The Economic Burden of Chronic Kidney Disease and End-Stage Renal Disease

Seminars in Nephrology

Volumn 36, Issue 4, 2016, Pages 319-330

  Wang, Virginia ^a,b   Vilme, Helene ^a   Maciejewski, Matthew L ^a,b   Boulware, L Ebony ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

Author keywords

Chronic kidney disease; costs; economics; end stage renal disease

Indexed keywords

ACCESS TO INFORMATION; CAREGIVER BURDEN; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; COST OF ILLNESS; DISEASE COURSE; DISEASE SEVERITY; ECONOMIC EVALUATION; END STAGE RENAL DISEASE; EVIDENCE BASED PRACTICE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH ECONOMICS; HEMODIALYSIS; HUMAN; PREVALENCE; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW; UNITED STATES; ABSENTEEISM; CHRONIC KIDNEY FAILURE; DISEASE EXACERBATION; ECONOMICS; PREMATURE MORTALITY; PRESENTEEISM; PRODUCTIVITY;

ABSENTEEISM; DISEASE PROGRESSION; EFFICIENCY; HEALTH CARE COSTS; HUMANS; KIDNEY FAILURE, CHRONIC; MORTALITY, PREMATURE; PRESENTEEISM; RENAL INSUFFICIENCY, CHRONIC;

EID: 84995426640     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2016.05.008     Document Type: Review

References (37)

1. 1 Gold, M.R., Siegel, J.E., Russell, L.B., Weinstein, M.C., Cost-effectiveness in health and medicine. 1996, Oxford University Press, New York.
2. 2 Arora, V., Moriates, C., Shah, N., The challenge of understanding health care costs and charges. AMA J Ethics 17 (2015), 1046–1052.
3. 3 Honeycutt, A.A., Segel, J.E., Zhuo, X., Hoerger, T.J., Imai, K., Williams, D., Medical costs of CKD in the Medicare population. J Am Soc Nephrol 24 (2013), 1478–1483.
4. 4 Trivedi, H., Cost implications of caring for chronic kidney disease: are interventions cost-effective?. Adv Chronic Kidney Dis 17 (2010), 265–270.
5. 5 US Renal Data System. USRDS 2014 annual data report: atlas of chronic kidney disease and end stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2014.
6. 6 Hall, Y.N., Rodriguez, R.A., Boyko, E.J., Chertow, G.M., O'Hare, A.M., Characteristics of uninsured Americans with chronic kidney disease. J Gen Intern Med 24 (2009), 917–922.
7. 7 Soni, A., Wright, J., Average annual health care use and expenditures for kidney disease among adults 18 and older, US Civilian Noninstutionalized Population, 2003-2007. 2010, Agency for Healthcare Research and Quality (AHRQ), Rockville, MD.
8. 8 US Renal Data System. USRDS 2015 annual data report: atlas of chronic kidney disease and end stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2015.
9. 9 Centers for Medicare and Medicaid Services (CMS), Medicare coverage of kidney dialysis and kidney transplant services. Baltimore, MD:. CMS, 2015.
10. 10 Centers for Disease Control and Prevention. Chronic kidney disease surveillance system-United States. [cited 2015]. Available from: https://nccd.cdc.gov/CKD/default.aspx. Accessed October 30, 2015.
11. 11 Smith, D.H., Gullion, C.M., Nichols, G., Keith, D.S., Brown, J.B., Cost of medical care for chronic kidney disease and comorbidity among enrollees in a large HMO population. J Am Soc Nephrol 15 (2004), 1300–1306.
12. 12 Vupputuri, S., Kimes, T.M., Calloway, M.O., et al. The economic burden of progressive chronic kidney disease among patients with type 2 diabetes. J Diabetes Complications 28 (2014), 10–16.
13. 13 Kubacki, M., Carter, C., Herrera, A.D., Wang, J., Lopez, J.M., Piech, C.T., Health plan retention and pharmacy costs of newly diagnosed patients with chronic kidney disease in a managed care population. Am Health Drug Benefits 2 (2009), 283–290.
14. 14 Smith, R.E. Jr., The clinical and economic burden of anemia. Am J Manag Care 16:Suppl (2010), S59–S66.
15. 15 London, R., Solis, A., Goldberg, G.A., Wade, S., Ryu, S., Health care resource utilization and the impact of anemia management in patients with chronic kidney disease. Am J Kidney Dis 40 (2002), 539–548.
16. 16 Moyneur, E., Bookhart, B.K., Mody, S.H., Fournier, A.A., Mallett, D., Duh, M.S., The economic impact of pre-dialysis epoetin alpha on health care and work loss costs in chronic kidney disease: an employer's perspective. Dis Manage 11 (2008), 49–58.
17. 17 Robbins, J.D., Kim, J.J., Zdon, G., Chan, W.W., Jones, J., Resource use and patient care associated with chronic kidney disease in a managed care setting. J Manag Care Pharm 9 (2003), 238–247.
18. 18 St Peter, W.L., Khan, S.S., Ebben, J.P., Pereira, B.J., Collins, A.J., Chronic kidney disease: the distribution of health care dollars. Kidney Int 66 (2004), 313–321.
19. 19 Gayomali, C., Sutherland, S., Finkelstein, F.O., The challenge for the caregiver of the patient with chronic kidney disease. Nephrol Dial Transplant 23 (2008), 3749–3751.
20. 20 Medway, M., Tong, A., Craig, J.C., et al. Parental perspectives on the financial impact of caring for a child with CKD. Am J Kidney Dis 65 (2015), 384–393.
21. 21 Muehrer, R.J., Schatell, D., Witten, B., Gangnon, R., Becker, B.N., Hofmann, R.M., Factors affecting employment at initiation of dialysis. Clin J Am Soc Nephrol 6 (2011), 489–496.
22. 22 Sullivan, S., Employer challenges with the chronic kidney disease population. J Manag Care Pharm 13:Suppl D (2007), S19–S21.
23. 23 Van der Mei, S.F., Kuiper, D., Groothoff, J.W., van den Heuvel, W.J., Van Son, W.J., Brouwer, S., Long-term health and work outcomes of renal transplantation and patterns of work status during the end-stage renal disease trajectory. J Occup Rehabil, 3, 2011, 325.
24. 24 Kutner, N.G., Zhang, R., Huang, Y., Johansen, K.L., Depressed mood, usual activity level, and continued employment after starting dialysis. Clin J Am Soc Nephrol 5 (2010), 2040–2045.
25. 25 National Alliance for Caregiving, and American Association of Retired Persons. Caregiving in the U.S. Bethesda, MD: National Alliance for Caregiving; 2015.
26. 26 Schulz, R., Beach, S.R., Caregiving as a risk factor for mortality: the Caregiver Health Effects Study. JAMA 282 (1999), 2215–2219.
27. 27 Mau, L.W., Liu, J., Qiu, Y., et al. Trends in patient characteristics and first-year medical costs of older incident hemodialysis patients, 1995-2005. Am J Kidney Dis 55 (2010), 549–557.
28. 28 Centers for Medicare and Medicaid Services. Medicare secondary payer. [cited 2016 February 1]. Available from: https://www.cms.gov/Medicare/Coordination-of-Benefits-and-Recovery/Coordination-of-Benefits-and-Recovery-Overview/Medicare-Secondary-Payer/Medicare-Secondary-Payer.html.
29. 29 Kossmann, R.J., From CKD to ESRD: a tale of two transitions. Adv Chronic Kidney Dis 18 (2011), 439–442.
30. 30 Murray, A.M., Cognitive impairment in the aging dialysis and chronic kidney disease populations: an occult burden. Adv Chronic Kidney Dis 15 (2008), 123–132.
31. 31 Stephens, J.M., Brotherton, S., Dunning, S.C., et al. Geographic disparities in patient travel for dialysis in the United States. J Rural Health 29 (2013), 339–348.
32. 32 Vats, H.S., Duffy, D.P., Assessment of self-perceived risk and driving safety in chronic dialysis patients. Dial Transplant 39 (2010), 1–6.
33. 33 National Institute of Diabetes and Digestive and Kidney Diseases, Home Hemodialysis. National Institutes of Health publication no. 08–6232. 2008, US Department of Health and Human Services, National Institutes of Health, Bethesda, MD.
34. 34 Ershler, W.B., Chen, K., Reyes, E.B., Dubois, R., Economic burden of patients with anemia in selected diseases. Value Health 8 (2005), 629–638.
35. 35 Kamal-Bahl, S.J., Pantely, S., Pyenson, B., Alexander, C.M., Employer-paid nonmedical costs for patients with diabetes and end-stage renal disease. Prev Chronic Dis, 3, 2006, A83.
36. 36 Feder, J., Nadel, M.V., Krishnan, M., A matter of choice: opportunities and obstacles facing people with ESRD. Clin J Am Soc Nephrol 11 (2016), 536–538.
37. 37 Nissenson, A.R., Wade, S., Goodnough, T., Knight, K., Dubois, R.W., Economic burden of anemia in an insured population. J Manag Care Pharm 11 (2005), 565–574.